摘要
背景:在之前的纵向随访调查研究中,除了睡眠呼吸性障碍(非呼吸暂停睡眠障碍 ,NSD)的睡眠障碍,特别是失眠和白天过渡性嗜睡已经被报导出高风险引发认知减退和痴呆。然而,大型的基于全国范围内人口研究可能进一步确认NSD与痴呆的关系。 方法:这是一次以全国范围内人口为基础的回顾性研究。我们使用了台湾全民健康保险研究资料库 (NHIRD)2000年1月至2011年12月的数据。NSD组包含了92079例20岁以上无痴呆病史的病人。对照组使用倾向评分1:1匹配了92079例对照。 痴呆案例的确定在2011年底截至。多元Cox风险比例回归分析被用来评价NSD组与非NSD组调整风险比率(aHRs)。 结果:在NSD与非NSD中,痴呆的发病率分别为4.19和2.95每1000人年,aHRs为1.46(95% CI=1.38-1.54;p<0.0001),痴呆的风险在性别和全年龄分组都要高,男性和年轻人群稍微高一点,分别为(aHR: 1.48, 95% CI=1.35–1.62, p<0.0001) 和(aHR: 2.79, 95% CI=1.63–4.78, p<0.0001)。痴呆最有可能在随访的第一年发生(aHR: 1.73, 95% CI=1.49–2.02; p<0.0001),但与对照组比较,NSD诊断后的5年痴呆的风险依旧很高。 结论:NSD可能是认知功能减退的早期指标,也是短期内痴呆的发病因素。它也长期提高了患痴呆的风险。NSD病人应该需要被密切监视认知减退。
关键词: 认知障碍,痴呆,流行病学,非呼吸暂停睡眠障碍,回顾性研究,睡眠障碍
Current Alzheimer Research
Title:Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder
Volume: 14 Issue: 3
Author(s): Pi-Shan Sung, Chih-Ching Yeh, Liang-Chao Wang, Peir-Haur Hung, Chih-Hsin Muo, Fung-Chang Sung, Chih-Hung Chen, Kuen-Jer Tsai.
Affiliation:
关键词: 认知障碍,痴呆,流行病学,非呼吸暂停睡眠障碍,回顾性研究,睡眠障碍
摘要: Background: Sleep disorders other than sleep apnea (non-apnea sleep disorder, NSD), esp. insomnia and excessive daytime sleepiness, has been reported to induce higher risk of cognitive decline and dementia in previous longitudinal follow-up studies. However, large-scale nationwide populationbased study may further confirm the association between NSD and dementia.
Methods: It was a nationwide population-based retrospective study. We used data from Taiwan’s National Health Insurance Research Database (NHIRD) between January 2000 and December 2011. The NSD cohort comprised 92,079 patients aged over 20 years with no preexisting dementia. The comparison cohort was propensity-score matched 1:1 with 92079 controls. Incident dementia cases were identified to the end of 2011. The NSD cohort to non-NSD cohort adjusted hazard ratios (aHRs) of dementia were assessed using multivariable Cox proportional hazards regression analysis. Results: Incidence of dementia was 4.19 and 2.95 per 1,000 person-years in the NSD and non-NSD cohorts, respectively, with an aHR of 1.46 (95% CI=1.38–1.54; p<0.0001). Risk of dementia was higher in both gender and whole age subgroup, with slightly higher in men (aHR: 1.48, 95% CI=1.35–1.62, p<0.0001) and in the younger population (aHR: 2.79, 95% CI=1.63–4.78, p<0.0001). Dementia was most likely to occur in the first year of follow-up (aHR: 1.73, 95% CI=1.49–2.02; p<0.0001), but dementia risk remained high 5 years after NSD diagnosis compared to controls (aHR: 1.44, 95% CI=1.32–1.57; p<0.0001). Conclusion: NSD may be an early indicator of decline in cognitive functioning and onset of dementia in the short-term period. It also carries a higher risk for dementia in the long run. Patients with NSD should require close monitoring for cognitive decline.Export Options
About this article
Cite this article as:
Pi-Shan Sung, Chih-Ching Yeh, Liang-Chao Wang, Peir-Haur Hung, Chih-Hsin Muo, Fung-Chang Sung, Chih-Hung Chen, Kuen-Jer Tsai. , Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666161108104703
DOI https://dx.doi.org/10.2174/1567205013666161108104703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Properties of Neurotoxic Peptides Related to the Bri Gene
Protein & Peptide Letters Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Epidemiological Aspects of Stroke in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology Tribute to Prof. Gerald Farin: Remembering A Geometric Modeling Researcher and Educator
Neuroscience and Biomedical Engineering (Discontinued) Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Protein Aggregation: Elucidation of the Mechanism and Determination of Associated Thermodynamic and Kinetic Parameters
Current Physical Chemistry Alzheimers Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
Current Drug Targets - CNS & Neurological Disorders Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Current Pharmaceutical Design The Endocannabinoid System and Huntingtons Disease
Current Drug Targets - CNS & Neurological Disorders Perspectives on Therapeutic Target for Multiple System Atrophy
Recent Patents on Regenerative Medicine Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Pharmacology of Voltage-Gated Proton Channels
Current Pharmaceutical Design Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research The Function and Integrity of the Neurovascular Unit Rests Upon the Integration of the Vascular and Inflammatory Cell Systems
Current Neurovascular Research Influence of Genetic Background on Apathy-Like Behavior in Triple Transgenic AD Mice
Current Alzheimer Research Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets